These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 4007273)

  • 61. WHO Expert Committee On Biological Standardization.
    World Health Organ Tech Rep Ser; 1998; 878():i-vi, 1-101. PubMed ID: 9731464
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genetic and biochemical factors affecting product consistency: introduction to the issues.
    Seamon KB
    Dev Biol Stand; 1992; 76():63-7. PubMed ID: 1478357
    [No Abstract]   [Full Text] [Related]  

  • 64. Shipment of biological materials: permits and packaging.
    Milewski E
    Recomb DNA Tech Bull; 1982 Sep; 5(3):139-46. PubMed ID: 6897457
    [No Abstract]   [Full Text] [Related]  

  • 65. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease.
    Mazurier C
    Semin Thromb Hemost; 2006 Jul; 32(5):529-36. PubMed ID: 16862527
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Autologous biologicals--science/regulations.
    Chapek ML; Brown KK; Lin BC
    Dev Biol (Basel); 2004; 117():33-41. PubMed ID: 15597614
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Studies on quality and safety control of drugs for human use from transgenic animals/clone animals].
    Hayakawa T; Toyoshima S; Yamaguchi T; Kawanishi T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2001; (119):1-26. PubMed ID: 11915277
    [TBL] [Abstract][Full Text] [Related]  

  • 69. WHO Expert Committee on Biological Standardization.
    World Health Organ Tech Rep Ser; 2002; 910():1-104, back cover. PubMed ID: 15497598
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genetic and phenotypic markers and their relationship to product quality and consistency.
    Adamson SR; Charlebois TS
    Dev Biol Stand; 1994; 83():31-44. PubMed ID: 7883098
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Industry perspective for biotech products.
    Möritz A
    Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Alternatives to animals in the development and control of biological products for human and veterinary use. The role of the European Pharmacopoeia.
    Artiges A
    Dev Biol Stand; 1999; 101():29-35. PubMed ID: 10566772
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genetic stability of rDNA production systems, a case report.
    Chiu YY
    Dev Biol Stand; 1994; 83():93-7. PubMed ID: 7883104
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Viral safety concept: application to blood and blood products].
    Trouvin JH
    Rev Prat; 2005 Nov; 55(18):2033-8. PubMed ID: 16419908
    [TBL] [Abstract][Full Text] [Related]  

  • 77. WHO Expert Committee on Biological Standardization.
    World Health Organization
    World Health Organ Tech Rep Ser; 2006; 932():v-vi, 1-137. PubMed ID: 17274191
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cell line issues: historical and future perspectives.
    Petricciani JC
    Dev Biol Stand; 1992; 76():5-11. PubMed ID: 1478355
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification of tobramycin impurities for quality control process monitoring using high-performance anion-exchange chromatography with integrated pulsed amperometric detection.
    Hanko VP; Rohrer JS; Liu HH; Zheng C; Zhang S; Liu X; Tang X
    J Pharm Biomed Anal; 2008 Aug; 47(4-5):828-33. PubMed ID: 18486398
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability.
    Davis GC; Beals JM; Johnson C; Mayer MH; Meiklejohn BI; Mitlak BH; Roth JL; Towns JK; Veenhuizen M
    Curr Med Res Opin; 2009 Jul; 25(7):1655-61. PubMed ID: 19476407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.